Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Implication of the Molecular Diagnostic Retinitis Pigmentosa Molecular Diagnostic Using High Throughput Sequencing (RP-SEQ-HD)

NCT02860520 is registered in ClinicalTrials.gov with University Hospital, Strasbourg, France as lead sponsor.

NCT NCT02860520
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02860520 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Implication of the Molecular Diagnostic Retinitis Pigmentosa Molecular Diagnostic Using High Throughput Sequencing (RP-SEQ-HD)
Lead sponsor
University Hospital, Strasbourg, France
Phase
Observational
Overall status
Unknown status
Start date
November 3, 2015
Completion date
August 31, 2025
Enrollment
500 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

retinitis pigmentosa